Law360, New York ( July 8, 2013, 12:21 PM EDT) -- On June 13, 2013, the U.S. Supreme Court handed down its long-awaited decision in Association for Molecular Pathology v. Myriad Genetics Inc., in which it found claims to isolated DNA not patent eligible under 35 U.S.C. § 101. The Myriad opinion is interesting not only in its own right, but also for how it illuminates the Supreme Court's recent approach to cases involving Section 101, an issue with a long and complex history reflecting a variety of legal tests and approaches....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.